COMPANY

TearSolutions

HQ: Charlottesville, VA source · tearsolutions.com ↗

Keywords: ophthalmology Neurotrophic Keratitis Primary Sjögren Syndrome Dry Eye Lacripep

Location: Charlottesville, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $517K (Form D filed Nov 10, 2025). SEC Form D 0001477932-25-008012 (Nov 10, 2025)
Evidence (1 event)
- Nov 10, 2025 · SEC Form D 0001477932-25-008012
  Name of Issuer: TearSolutions, Inc.; CIK: 1611687; Address: Charlottesville, VA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 517000; Total Amount Sold: 517000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Feb 19, 2026 Trial start Phase 2: A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis source ↗
Nov 21, 2024 Raise Private equity round — Series B: $3M (total, as published), announced Nov 21, 2024. Source: company release on GlobeNewswire. source ↗
Jun 30, 2017 Trial start Phase 1/Phase 2: Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome source ↗

2027-02 (ESTIMATED) · Phase 2 · A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis · NCT07568730

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $3.0M. Last 2 years.

Nov 21, 2024 Private equity round — Series B: $3M (total, as published), announced Nov 21, 2024. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07568730	A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis	Phase 2	Recruiting	Feb 19, 2026	2027-02 (estimated)
NCT03226444	Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome	Phase 1/Phase 2	Completed	Jun 30, 2017	Dec 27, 2019 (actual)